XML 39 R25.htm IDEA: XBRL DOCUMENT
v3.21.2

BUSINESS COMBINATIONS (Tables) | 9 Months Ended
--- | ---
Jun. 30, 2021
Pre-Clinical Research Services, Inc. |
Business Acquisition [Line Items] |
Schedule of purchase price allocation |
​ | ​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | June 30, 2021
Assets acquired and liabilities assumed: |  | ​ |
Receivables | ​ | $ | 578
Property and equipment | ​ |  | 2,836
Unbilled receivables | ​ | ​ | 162
Prepaid expenses | ​ |  | 27
Intangible assets | ​ | ​ | 2,081
Goodwill | ​ | ​ | 751
Accounts payable | ​ | ​ | (109)
Accrued expenses | ​ |  | (118)
Customer advances | ​ |  | (351)
​ | ​ | $ | 5,857
HistoTox Labs |
Business Acquisition [Line Items] |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | Preliminary
​ | ​ | Allocation as of
​ | ​ | June 30, 2021
Assets acquired and liabilities assumed: |  | ​
Receivables | ​ | ​ | 1,020
Prepaid expenses | ​ | ​ | 40
Operating lease ROU | ​ | ​ | 2,239
Property and equipment | ​ |  | 4,021
Intangible assets | ​ | ​ | 8,500
Other Assets | ​ | ​ | 35
Goodwill | ​ | ​ | 9,386
Accounts payable | ​ | ​ | (128)
Customer advances | ​ | ​ | (553)
Operating lease liability | ​ |  | (2,239)
​ | ​ | $ | 22,321
Bolder BioPATH |
Business Acquisition [Line Items] |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | Preliminary
​ | ​ | Allocation as of
​ | ​ | June 30, 2021
Assets acquired and liabilities assumed: |  | ​ |
Cash and cash equivalents | ​ | $ | 124
Receivables | ​ | ​ | 2,278
Unbilled receivables | ​ | ​ | 1,867
Prepaid expenses | ​ |  | 103
Operating lease ROU | ​ | ​ | 2,750
Property and equipment | ​ |  | 6,609
Intangible assets | ​ | ​ | 12,500
Other assets | ​ | ​ | 70
Goodwill | ​ | ​ | 31,996
Accounts payable | ​ | ​ | (93)
Accrued expenses | ​ |  | (279)
Deferred revenue | ​ | ​ | (723)
Operating lease liability | ​ |  | (2,750)
​ | ​ | $ | 54,452
Schedule of unaudited pro forma information | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Three Months Ended | ​ | Three Months Ended | ​ | Nine Months Ended | ​ | Nine Months Ended | ​
​ | June 30, 2021 | ​ | June 30, 2020 | ​ | June 30, 2021 | ​ | June 30, 2020 |
Total revenues | $ | 24,786 | ​ | $ | 21,448 | ​ | $ | 72,789 | ​ | $ | 62,661 | ​
​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
Net (loss) income |  | (1,847) | ​ |  | 375 | ​ |  | 6,280 | ​ |  | 996 | ​
​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Pro forma basic net (loss) income per share | $ | (0.13) | ​ | $ | 0.03 | ​ | $ | 0.45 | ​ | $ | 0.08 | ​
Pro forma diluted net income per share | $ | (0.13) | ​ | $ | 0.03 | ​ | $ | 0.45 | ​ | $ | 0.08 | ​

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_PreClinicalResearchServicesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_HistotoxLabsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_BolderBioPTHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |